NO981961L - FremgangsmÕte og farmas÷ytisk blanding for regulering av lipidkonsentrasjon - Google Patents

FremgangsmÕte og farmas÷ytisk blanding for regulering av lipidkonsentrasjon

Info

Publication number: NO981961L
Authority: NO; Norway
Prior art keywords: combination; methylethyl; pharmaceutical composition; concentration control; lipid concentration
Prior art date: 1995-11-02

Application number

NO981961A

Other languages

English (en)

Norwegian (no)

Other versions

NO981961D0 (no

Inventor

Thomas M A Bocan

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-02

Filing date

1998-04-30

Publication date

1998-05-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21719566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO981961(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-04-30 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

1998-04-30 Publication of NO981961D0 publication Critical patent/NO981961D0/no

1998-05-04 Publication of NO981961L publication Critical patent/NO981961L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO981961A 1995-11-02 1998-04-30 FremgangsmÕte og farmas÷ytisk blanding for regulering av lipidkonsentrasjon NO981961L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US615595P	1995-11-02	1995-11-02
PCT/US1996/015854 WO1997016184A1 (fr)	1995-11-02	1996-10-02	Procede et composition pharmaceutique visant a reguler la concentration lipidique

Publications (2)

Publication Number	Publication Date
NO981961D0 NO981961D0 (no)	1998-04-30
NO981961L true NO981961L (no)	1998-05-04

Family

ID=21719566

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO981961A NO981961L (no)	1995-11-02	1998-04-30	FremgangsmÕte og farmas÷ytisk blanding for regulering av lipidkonsentrasjon

Country Status (27)

Country	Link
US (3)	US6124309A (fr)
EP (1)	EP0858336B1 (fr)
JP (1)	JPH11515025A (fr)
KR (2)	KR100449604B1 (fr)
CN (2)	CN1679953A (fr)
AR (1)	AR004527A1 (fr)
AT (1)	ATE348607T1 (fr)
AU (1)	AU720853B2 (fr)
BG (1)	BG64018B1 (fr)
BR (1)	BR9611410A (fr)
CZ (1)	CZ127198A3 (fr)
DE (1)	DE69636783T2 (fr)
EA (1)	EA000514B1 (fr)
ES (1)	ES2279526T3 (fr)
GE (1)	GEP20001898B (fr)
HK (1)	HK1016509A1 (fr)
HU (1)	HUP9901865A3 (fr)
IL (1)	IL123902A (fr)
IS (1)	IS4720A (fr)
NO (1)	NO981961L (fr)
NZ (2)	NZ319906A (fr)
PL (1)	PL186714B1 (fr)
RO (1)	RO120816B1 (fr)
SK (1)	SK284142B6 (fr)
UA (1)	UA46069C2 (fr)
WO (1)	WO1997016184A1 (fr)
ZA (1)	ZA969187B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6268392B1 (en) *	1994-09-13	2001-07-31	G. D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
GEP20001898B (en) *	1995-11-02	2000-01-05	Warner Lambert Co	Method and Pharmaceutical Composition for Regulating Lipid Concentration with Mam
EP1514543A1 (fr) *	1997-08-29	2005-03-16	Pfizer Inc.	Ttherapie combinee utilisant de l'atorvastatine et un antihypertenseur
GT199800126A (es) *	1997-08-29	2000-01-29		Terapia de combinacion.
GT199800127A (es) *	1997-08-29	2000-02-01		Combinaciones terapeuticas.
AU1591699A (en) *	1998-03-17	1999-10-11	Warner-Lambert Company	Statin-matrix metalloproteinase inhibitor combinations
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
EE200100199A (et) *	1998-09-30	2002-06-17	Warner-Lambert Company	Kateetrilpõhineva revaskularisatsiooni ennetamisevõi edasilükkamise meetod
CO5140104A1 (es) *	1999-02-16	2002-03-22	Novartis Ag	Derivados de mevinolina y preparacion farmaceuticas que los contienen
US20010006656A1 (en) *	1999-02-17	2001-07-05	University Of Washington	Methods and compositions for inhibiting inflammation associated with pulmonary disease
WO2001022962A1 (fr) *	1999-09-30	2001-04-05	Merck & Co., Inc.	Combinaison anti-hypercholesterolemique
EP1092432A1 (fr)	1999-10-15	2001-04-18	Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.)	Composes anti-ischemiques
KR20020050257A (ko) *	1999-11-05	2002-06-26	로즈 암스트롱, 크리스틴 에이. 트러트웨인	Ａｃａｔ 저해제에 의한 플라크 파열의 방지
PL362244A1 (en) *	2000-09-01	2004-10-18	Sankyo Company, Limited	Medicinal compositions
US20040122091A1 (en) *	2000-10-11	2004-06-24	Esperion Therapeutics, Inc.	Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
CN1479721A (zh)	2000-10-11	2004-03-03	ͨ��ҽ�ƹ�˾	用于胆固醇治疗和相关应用的亚砜和双亚砜化合物和组合物
EP1326822A2 (fr)	2000-10-11	2003-07-16	Esperion Therapeutics Inc.	Composes de fonction cetone et compositions pour la regulation du taux de cholesterol, et utilisations associees
MXPA03003021A (es)	2000-10-11	2003-07-14	Esperion Therapeutics Inc	Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
CA2425674A1 (fr)	2000-10-11	2002-04-18	Jean-Louis H. Dasseux	Composes et compositions de sulfure et de disulfure pour le traitement du cholesterol et utilisations associees
US7304093B2 (en) *	2000-10-11	2007-12-04	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
CA2369967A1 (fr) *	2001-02-12	2002-08-12	Joseph Anthony Cornicelli	Methodes de traitement de maladies et de troubles relies au facteur nucleaire-kappa b
US20030114497A1 (en) *	2001-07-31	2003-06-19	Laman Alani	Pharmaceutical compositions of amlodipine and atorvastatin
US20040204502A1 (en) *	2001-10-11	2004-10-14	Dasseux Jean-Louis Henri	Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20050020694A1 (en) *	2001-10-11	2005-01-27	Dasseux Jean-Louis Henri	Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US20040192771A1 (en) *	2001-10-11	2004-09-30	Dasseux Jean-Louis Henri	Ether compounds and compositions for cholesterol management and related uses
WO2003077896A1 (fr) *	2002-03-12	2003-09-25	Merck & Co., Inc.	Therapie par association de medicaments
WO2003087040A2 (fr) *	2002-04-10	2003-10-23	Esperion Therapeutics, Inc.	Mimiques d'acyl-coenzyme a comprenant des derives de pantolactone et d'acide pantothenique, leurs compositions, methodes de regulation du taux de cholesterol et utilisations associees
JP4187141B2 (ja) *	2002-04-12	2008-11-26	興和株式会社	新規なトロンボモジュリン発現促進剤
PT2404890T (pt)	2003-01-23	2017-10-23	Esperion Therapeutics Inc	Compostos de hidroxilo e composições para gestão do colesterol e utilizações relacionadas
JPWO2005020996A1 (ja)	2003-08-29	2007-11-01	興和株式会社	リピド・リッチ・プラークの安定化方法及び破裂予防方法
WO2005046706A1 (fr) *	2003-11-17	2005-05-26	Toyo Shinyaku Co., Ltd.	Agent ameliorant le lipometabolisme contenant un extrait d'ecorce du pin
BR0318685A (pt)	2003-12-24	2006-12-19	Esperion Therapeutics Inc	compostos de cetona e composições para controle de colesterol e usos relacionados
US20050234068A1 (en) *	2004-04-19	2005-10-20	Baldwin Dalton D	Composition and method of decreasing renal ischemic damage
TW200605890A (en) *	2004-07-28	2006-02-16	Sankyo Co	Pharmaceutical compositions for inhibiting arteriosclerosis
RU2007115900A (ru) *	2004-10-27	2008-11-10	Дайити Санкио Компани, Лимитед (Jp)	Производные бензола, имеющие 2 или более заместителей
TW200619204A (en) *	2004-12-10	2006-06-16	Kowa Co	Method for reduction, stabilization and prevention of rupture of lipid rich plaque
WO2007054896A1 (fr) *	2005-11-08	2007-05-18	Ranbaxy Laboratories Limited	Procede de preparation de sel hemicalcique d’acide (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoique
US9597289B2 (en)	2006-04-26	2017-03-21	Rosemont Pharmaceuticals Ltd.	Liquid oral simvastatin compositions
US20130254787A1 (en)	2006-05-02	2013-09-26	Invidi Technologies Corporation	Method and apparatus to perform real-time audience estimation and commercial selection suitable for targeted advertising
US20070269503A1 (en) *	2006-05-16	2007-11-22	James Walter Burgess	Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
US8314080B2 (en)	2010-04-06	2012-11-20	Kuwait University	Method of treating type I diabetes
CN102424663B (zh) *	2010-12-03	2013-08-14	天津滨江药物研发有限公司	一种阿托伐他汀氨基酸盐及其制备方法
US8586527B2 (en) *	2011-10-20	2013-11-19	Jaipal Singh	Cerivastatin to treat pulmonary disorders
EA201891154A1 (ru)	2011-10-28	2019-02-28	ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи	Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
CN103304496A (zh) *	2012-03-08	2013-09-18	南京工业大学	一种合成申嗪霉素方法
WO2013171100A1 (fr)	2012-05-16	2013-11-21	Joachim Hans	Acides triterpènes pentacyliques polyhydroxylés en tant qu'inhibiteurs d'hmg-coa réductase
NZ736344A (en)	2015-03-13	2024-08-30	Esperion Therapeutics Inc	Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr)	2015-03-16	2018-01-23	Esperion Therapeutics Inc	Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2020257573A1 (fr)	2019-06-21	2020-12-24	Esperion Therapeutics, Inc.	Formes salines d'acide bempedoïque et leurs procédés d'utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4739073A (en) *	1983-11-04	1988-04-19	Sandoz Pharmaceuticals Corp.	Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
CA2003478A1 (fr) *	1988-12-12	1990-06-12	Leonard G. Dennick	Combinaison d'un inhibiteur de hmg coa reductase et d'un autre type d'agent reducteur du cholesterol serique et methode de reduction du cholesterol serique par l'emploi de ladite combinaison
FI94339C (fi) *	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2048395A1 (fr) *	1990-08-23	1992-02-24	Henry Y. Pan	Methode de traitement ou de prevention de l'apparition d'une hyperlipoproteinemie de type iii.
HUT67341A (en)	1991-07-23	1995-03-28	Schering Corp	Substituted beta-lactam compounds useful as hypocholesterolemic agents, pharmaceutical compositions containing the same and process for the production thereof
WO1994009774A1 (fr) *	1992-10-26	1994-05-11	Merck & Co., Inc.	Composes biologiquement actifs et leur procede de fabrication
LT3300B (en)	1992-12-23	1995-06-26	Schering Corp	Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
IL109431A (en) *	1993-05-14	2001-01-11	Warner Lambert Co	Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5491172A (en) *	1993-05-14	1996-02-13	Warner-Lambert Company	N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
WO1995013063A1 (fr) *	1993-11-09	1995-05-18	Merck & Co., Inc.	Inhibiteurs de l'hmg-coa reductase dans la normalisation des troubles de l'endothelium vasculaire
GEP20001898B (en) *	1995-11-02	2000-01-05	Warner Lambert Co	Method and Pharmaceutical Composition for Regulating Lipid Concentration with Mam

1996
- 1996-10-02 GE GEAP19964269A patent/GEP20001898B/en unknown
- 1996-10-02 UA UA98052811A patent/UA46069C2/uk unknown
- 1996-10-02 KR KR10-1998-0703240A patent/KR100449604B1/ko not_active IP Right Cessation
- 1996-10-02 SK SK557-98A patent/SK284142B6/sk unknown
- 1996-10-02 CZ CZ981271A patent/CZ127198A3/cs unknown
- 1996-10-02 BR BR9611410A patent/BR9611410A/pt not_active Application Discontinuation
- 1996-10-02 ES ES96934020T patent/ES2279526T3/es not_active Expired - Lifetime
- 1996-10-02 WO PCT/US1996/015854 patent/WO1997016184A1/fr not_active Application Discontinuation
- 1996-10-02 NZ NZ319906A patent/NZ319906A/en unknown
- 1996-10-02 RO RO98-00919A patent/RO120816B1/ro unknown
- 1996-10-02 AU AU72539/96A patent/AU720853B2/en not_active Ceased
- 1996-10-02 NZ NZ512484A patent/NZ512484A/xx unknown
- 1996-10-02 EA EA199800420A patent/EA000514B1/ru not_active IP Right Cessation
- 1996-10-02 EP EP96934020A patent/EP0858336B1/fr not_active Revoked
- 1996-10-02 US US09/051,368 patent/US6124309A/en not_active Expired - Fee Related
- 1996-10-02 IL IL12390296A patent/IL123902A/xx not_active IP Right Cessation
- 1996-10-02 CN CNA2005100517235A patent/CN1679953A/zh active Pending
- 1996-10-02 HU HU9901865A patent/HUP9901865A3/hu unknown
- 1996-10-02 DE DE69636783T patent/DE69636783T2/de not_active Expired - Fee Related
- 1996-10-02 PL PL96326365A patent/PL186714B1/pl not_active IP Right Cessation
- 1996-10-02 AT AT96934020T patent/ATE348607T1/de not_active IP Right Cessation
- 1996-10-02 CN CN961980109A patent/CN1217656C/zh not_active Expired - Fee Related
- 1996-10-02 JP JP9517342A patent/JPH11515025A/ja not_active Ceased
- 1996-10-02 KR KR10-2004-7003107A patent/KR20040029459A/ko active Search and Examination
- 1996-10-31 ZA ZA969187A patent/ZA969187B/xx unknown
- 1996-11-01 AR ARP960105005A patent/AR004527A1/es unknown
1998
- 1998-04-17 IS IS4720A patent/IS4720A/is unknown
- 1998-04-29 BG BG102417A patent/BG64018B1/bg unknown
- 1998-04-30 NO NO981961A patent/NO981961L/no unknown
1999
- 1999-04-21 HK HK99101732A patent/HK1016509A1/xx not_active IP Right Cessation
- 1999-07-01 US US09/345,944 patent/US6093719A/en not_active Expired - Fee Related
- 1999-07-01 US US09/346,503 patent/US6143755A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NZ512484A (en)	2003-02-28
ES2279526T3 (es)	2007-08-16
SK55798A3 (en)	1999-06-11
DE69636783D1 (de)	2007-02-01
JPH11515025A (ja)	1999-12-21
EP0858336B1 (fr)	2006-12-20
PL186714B1 (pl)	2004-02-27
HK1016509A1 (en)	1999-11-05
CZ127198A3 (cs)	1998-12-16
CN1201389A (zh)	1998-12-09
KR100449604B1 (ko)	2004-11-16
ZA969187B (en)	1997-05-29
SK284142B6 (sk)	2004-10-05
HUP9901865A2 (hu)	1999-10-28
AU7253996A (en)	1997-05-22
BG102417A (en)	1999-01-29
IL123902A (en)	2003-01-12
BG64018B1 (bg)	2003-10-31
ATE348607T1 (de)	2007-01-15
KR20040029459A (ko)	2004-04-06
EA199800420A1 (ru)	1998-10-29
HUP9901865A3 (en)	2000-06-28
CN1217656C (zh)	2005-09-07
IL123902A0 (en)	1998-10-30
NZ319906A (en)	2000-02-28
UA46069C2 (uk)	2002-05-15
AR004527A1 (es)	1998-12-16
US6124309A (en)	2000-09-26
DE69636783T2 (de)	2007-10-18
IS4720A (is)	1998-04-17
PL326365A1 (en)	1998-09-14
US6143755A (en)	2000-11-07
BR9611410A (pt)	1999-01-05
KR19990067270A (ko)	1999-08-16
US6093719A (en)	2000-07-25
GEP20001898B (en)	2000-01-05
EP0858336A1 (fr)	1998-08-19
WO1997016184A1 (fr)	1997-05-09
RO120816B1 (ro)	2006-08-30
CN1679953A (zh)	2005-10-12
NO981961D0 (no)	1998-04-30
EA000514B1 (ru)	1999-10-28
AU720853B2 (en)	2000-06-15

Publication	Publication Date	Title
NO981961L (no)	1998-05-04	FremgangsmÕte og farmas÷ytisk blanding for regulering av lipidkonsentrasjon
MX9702204A (es)	1997-06-28	Tratamiento con ribozimas de enfermedades o condiciones relacionadas con niveles de lipoproteina (a) [lp(a)] en plasma, inhibiendo apolipoproteina (a) [apo(a)].
Fairbanks et al.	1984	Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor.
Ginsberg	1998	Effects of statins on triglyceride metabolism
NO20013161L (no)	2001-08-17	Preparater av ileum-gallesyretransportinhibitorer og kolesterylesteroverföringsproteininhibitorer for kardiovaskul¶reindikasjoner
EE9400341A (et)	1996-04-15	Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon
NO20100214L (no)	2001-11-21	Preparat for a redusere LIPG ekspresjon hos en pasient og anvendelsen av dette
DE69628874D1 (de)	2003-08-07	Verwendung eines HMG CoA-Reduktase Inhibitors zur Vorbeugung eines zweiten Herzanfalls
Clay et al.	2001	Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins
FI951218A0 (fi)	1995-03-15	Menetelmä kokonaiskolesterolin ja matalatiheyksisen lipoproteiinikolestrolin pitoisuuksien pienentämiseksi veressä
DE69115909D1 (de)	1996-02-08	Verwendung von Phospholipiden zur Herstellung eines topischen Arzneimittels zur Beinflussung des Serumcholesterinspiegels
Carson	1987	Tissue factor (coagulation factor III) inhibition by apolipoprotein A-II.
Register et al.	1984	Effect of vanadate, a potent alkaline phosphatase inhibitor, on 45Ca and 32Pi uptake by matrix vesicle-enriched fractions from chicken epiphyseal cartilage.
Zieve et al.	1972	Post-heparin phospholipase and post-heparin lipase have different tissue origins
Bergstrom et al.	1998	Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin
DE69429816D1 (de)	2002-03-21	C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
ATE353957T1 (de)	2007-03-15	Verwendung von lezithin-cholesterin- azetyltransferase für die behandlung von atherosklerose
NO934832L (no)	1994-06-29	Farmasöytisk sammensetning for forhindring eller behandling av arterioscherose
Cromwell et al.	2000	Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors
CA2233558A1 (fr)	1997-05-09	Procede et composition pharmaceutique visant a reguler la concentration lipidique
AU7384194A (en)	1995-02-06	Lining board with a support with an approximately u-shaped cross section
Pioruńska-Stolzmann et al.	2001	The influence of simvastatin on lipase and cholesterol esterase activity in the serum of men with coronary heart disease
Tsimikas et al.	2024	Obicetrapib Demonstrates Significant Deductions of LP (A) on Top of High-Intensity Statins
Humble et al.	1994	Studies on rat liver phosphatidate phosphohydrolase and plasma lipids: effect of HMG-CoA reductase inhibitors
Bevilacqua et al.	1995	Effects of fluvastatin on lipids profiles and t-PA mass concentration in coronary patients with primary hypercholesterolemia and high LP (a)